Compositional and Functional Alterations in Intestinal Microbiota in Patients with Psychosis or Schizophrenia: A Systematic Review and Meta-analysis.
microbiome
microbiota
psychosis
schizophrenia
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
07 09 2023
07 09 2023
Historique:
pmc-release:
20
05
2024
medline:
8
9
2023
pubmed:
21
5
2023
entrez:
21
5
2023
Statut:
ppublish
Résumé
Intestinal microbiota is intrinsically linked to human health. Evidence suggests that the composition and function of the microbiome differs in those with schizophrenia compared with controls. It is not clear how these alterations functionally impact people with schizophrenia. We performed a systematic review and meta-analysis to combine and evaluate data on compositional and functional alterations in microbiota in patients with psychosis or schizophrenia. Original studies involving humans and animals were included. The electronic databases PsycINFO, EMBASE, Web of Science, PubMed/MEDLINE, and Cochrane were systematically searched and quantitative analysis performed. Sixteen original studies met inclusion criteria (1376 participants: 748 cases and 628 controls). Ten were included in the meta-analysis. Although observed species and Chao 1 show a decrease in diversity in people with schizophrenia compared with controls (SMD = -0.14 and -0.66 respectively), that did not reach statistical significance. We did not find evidence for variations in richness or evenness of microbiota between patients and controls overall. Differences in beta diversity and consistent patterns in microbial taxa were noted across studies. We found increases in Bifidobacterium, Lactobacillus, and Megasphaera in schizophrenia groups. Variations in brain structure, metabolic pathways, and symptom severity may be associated with compositional alterations in the microbiome. The heterogeneous design of studies complicates a similar evaluation of functional readouts. The microbiome may play a role in the etiology and symptomatology of schizophrenia. Understanding how the implications of alterations in microbial genes for symptomatic expression and clinical outcomes may contribute to the development of microbiome targeted interventions for psychosis.
Sections du résumé
BACKGROUND AND HYPOTHESIS
Intestinal microbiota is intrinsically linked to human health. Evidence suggests that the composition and function of the microbiome differs in those with schizophrenia compared with controls. It is not clear how these alterations functionally impact people with schizophrenia. We performed a systematic review and meta-analysis to combine and evaluate data on compositional and functional alterations in microbiota in patients with psychosis or schizophrenia.
STUDY DESIGN
Original studies involving humans and animals were included. The electronic databases PsycINFO, EMBASE, Web of Science, PubMed/MEDLINE, and Cochrane were systematically searched and quantitative analysis performed.
STUDY RESULTS
Sixteen original studies met inclusion criteria (1376 participants: 748 cases and 628 controls). Ten were included in the meta-analysis. Although observed species and Chao 1 show a decrease in diversity in people with schizophrenia compared with controls (SMD = -0.14 and -0.66 respectively), that did not reach statistical significance. We did not find evidence for variations in richness or evenness of microbiota between patients and controls overall. Differences in beta diversity and consistent patterns in microbial taxa were noted across studies. We found increases in Bifidobacterium, Lactobacillus, and Megasphaera in schizophrenia groups. Variations in brain structure, metabolic pathways, and symptom severity may be associated with compositional alterations in the microbiome. The heterogeneous design of studies complicates a similar evaluation of functional readouts.
CONCLUSIONS
The microbiome may play a role in the etiology and symptomatology of schizophrenia. Understanding how the implications of alterations in microbial genes for symptomatic expression and clinical outcomes may contribute to the development of microbiome targeted interventions for psychosis.
Identifiants
pubmed: 37210594
pii: 7175082
doi: 10.1093/schbul/sbad049
pmc: PMC10483467
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1239-1255Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Neuropsychiatr Dis Treat. 2019 Nov 19;15:3219-3229
pubmed: 31819450
Psychopharmacology (Berl). 2019 May;236(5):1671-1685
pubmed: 30155748
Behav Brain Res. 2020 Feb 3;379:112374
pubmed: 31759045
Front Psychiatry. 2021 Jul 30;12:685910
pubmed: 34393849
Cell Mol Neurobiol. 2018 Aug;38(6):1197-1206
pubmed: 29802603
Gut Pathog. 2020 Feb 03;12:6
pubmed: 32025243
Gastroenterology. 2016 Nov;151(5):836-844
pubmed: 27521479
Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
pubmed: 17909124
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Gastroenterol Clin North Am. 2019 Sep;48(3):407-431
pubmed: 31383279
Nat Med. 2021 Nov;27(11):1885-1892
pubmed: 34789871
PeerJ. 2015 Aug 25;3:e1140
pubmed: 26336637
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Curr Opin Psychiatry. 2015 Jan;28(1):1-6
pubmed: 25415497
Pharmaceuticals (Basel). 2018 Jun 25;11(3):
pubmed: 29941795
Oncotarget. 2017 May 10;8(32):53829-53838
pubmed: 28881854
Biol Psychiatry. 2019 Jan 15;85(2):150-163
pubmed: 30064690
Microorganisms. 2022 Sep 11;10(9):
pubmed: 36144422
Schizophr Res. 2019 Feb;204:23-29
pubmed: 30268819
Mol Psychiatry. 2016 Jun;21(6):738-48
pubmed: 27090305
JAMA Psychiatry. 2021 Dec 1;78(12):1343-1354
pubmed: 34524405
Acta Pharmacol Sin. 2018 May;39(5):733-753
pubmed: 29565038
Front Cell Infect Microbiol. 2017 Nov 30;7:489
pubmed: 29250490
Biochem Biophys Res Commun. 2019 Apr 30;512(2):373-380
pubmed: 30898321
Psychopharmacology (Berl). 2012 May;221(1):155-69
pubmed: 22234378
HRB Open Res. 2021 Sep 29;4:108
pubmed: 34870091
Schizophr Res. 2018 Jul;197:470-477
pubmed: 29352709
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):585-595
pubmed: 28790452
Mol Psychiatry. 2016 Jun;21(6):786-96
pubmed: 27067014
Biol Psychiatry. 2020 Feb 1;87(3):215-224
pubmed: 31561858
Front Behav Neurosci. 2019 Jun 04;13:123
pubmed: 31231198
Neuropsychopharmacology. 2016 Sep;41(10):2587-95
pubmed: 27143602
Curr Dev Disord Rep. 2016 Mar;3(1):75-81
pubmed: 27398286
Brain Commun. 2021 Jun 01;3(2):fcab113
pubmed: 34704023
Schizophr Res. 2018 Feb;192:398-403
pubmed: 28442250
Behav Brain Res. 2015 Jan 15;277:32-48
pubmed: 25078296
Front Cell Infect Microbiol. 2019 Feb 04;9:4
pubmed: 30778376
Front Psychiatry. 2020 Jun 26;11:623
pubmed: 32670122
Mol Psychiatry. 2022 Apr;27(4):1920-1935
pubmed: 35194166
Transl Psychiatry. 2021 May 27;11(1):322
pubmed: 34045446
Endocr Pract. 2016 Oct;22(10):1224-1234
pubmed: 27409822
Dig Dis Sci. 2020 Mar;65(3):818-828
pubmed: 32056091
J Parkinsons Dis. 2019;9(s2):S297-S312
pubmed: 31498131
Curr Psychiatry Rep. 2015 May;17(5):27
pubmed: 25773227
Brain Behav Immun. 2020 Mar;85:120-127
pubmed: 31255682
Parkinsonism Relat Disord. 2022 Jan;94:1-9
pubmed: 34844021
World Psychiatry. 2017 Jun;16(2):121-129
pubmed: 28498595
Brain Behav Immun. 2021 Jan;91:245-256
pubmed: 33098964
Neuropsychobiology. 2019;78(1):1-6
pubmed: 30947230
Protein Cell. 2010 Aug;1(8):718-25
pubmed: 21203913
Sci Adv. 2019 Feb 06;5(2):eaau8317
pubmed: 30775438
Front Psychiatry. 2020 Mar 12;11:156
pubmed: 32226399
Nature. 2012 Sep 13;489(7415):220-30
pubmed: 22972295
Int J Neuropsychopharmacol. 2019 Jan 1;22(1):37-52
pubmed: 30099552
Neurogastroenterol Motil. 2013 Sep;25(9):713-9
pubmed: 23910373
PeerJ. 2020 Jul 29;8:e9574
pubmed: 32821537
Mol Psychiatry. 2020 Nov;25(11):2905-2918
pubmed: 31391545
Child Neurol Open. 2018 Jul 11;5:2329048X18786799
pubmed: 30023407
Neurosci Biobehav Rev. 2020 May;112:227-241
pubmed: 32032654
Physiol Rev. 2019 Oct 1;99(4):1877-2013
pubmed: 31460832
Cell. 2015 Apr 9;161(2):264-76
pubmed: 25860609
Ir J Psychol Med. 2018 Jun;35(2):89-94
pubmed: 30115193
J Affect Disord. 2018 Mar 1;228:13-19
pubmed: 29197739
Curr Pharm Des. 2016;22(40):6134-6141
pubmed: 27634184
Mol Psychiatry. 2014 Dec;19(12):1252-7
pubmed: 25288135
J Psychiatr Res. 2018 Apr;99:50-61
pubmed: 29407287
J Nerv Ment Dis. 2003 Sep;191(9):568-73
pubmed: 14504565
Neurogastroenterol Motil. 2011 Mar;23(3):187-92
pubmed: 21303428
EBioMedicine. 2021 Apr;66:103307
pubmed: 33819741
ISME J. 2016 Aug;10(8):1866-76
pubmed: 26872040
Sci Rep. 2021 May 7;11(1):9743
pubmed: 33963227
Psychiatry Res. 2020 Sep;291:113260
pubmed: 32763534
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Apr 5;42:5-19
pubmed: 22800757
Mol Psychiatry. 2022 Jan;27(1):141-153
pubmed: 33558650
Brief Bioinform. 2021 Jan 18;22(1):140-145
pubmed: 31813948
Nat Commun. 2020 Mar 31;11(1):1612
pubmed: 32235826
Philos Trans R Soc Lond B Biol Sci. 2018 Mar 19;373(1742):
pubmed: 29352031
Biomolecules. 2022 Jul 18;12(7):
pubmed: 35883554
J Psychiatr Res. 2020 Apr;123:136-144
pubmed: 32065949
Horm Behav. 2018 Mar;99:41-49
pubmed: 29427583
Adv Nutr. 2021 Jul 30;12(4):1239-1285
pubmed: 33693453
N Engl J Med. 2016 Dec 15;375(24):2369-2379
pubmed: 27974040
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120